Phase II Trial of Paclitaxel and Cixutumumab in Metastatic Esophageal Cancer
A randomized phase II trial is evaluating the efficacy of paclitaxel with or without cixutumumab in metastatic esophageal cancer.
Asset / Drug
Drug and asset intelligence for Paclitaxel with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Chemotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.